NCT04460820已完成不适用
A Randomized,Open-label, Single-Dose,Two-Cycle,Crossover Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Under Advanced Breast Cancers
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2019年7月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
A Randomized,Open-label, Single-Dose,Two-Cycle,Cross- Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Under Advanced Breast Cancers.
详细描述
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection , 20 mg:10 mL (CSPC OuYi Pharmaceutical Technology Co, Ltd), and Caelyx®, 20 mg:10 mL (Janssen-Cilag International NV), in Advanced Breast Cancers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •1.Voluntary agreement to provide written informed consent. 2.Patients with locally advanced or metastatic breast cancer diagnosed by histology or cytology，and who may benefit from monotherapy of Doxorubicin liposomes.
- •3.Females age 18 to 75 years, inclusive. 4.Body weight ≥45.0 kg, and BSA<1.80m
- •5.The ECOG performance status is 0 to
- •6.The expected survival time is more than 3 months. 7.Subjects must have laboratory values within the limits described below: ANC ≥1.5 x 109/L PLT ≥100 x 109/L HB ≥90 g/L PT/INR and APTT ≤1.5 x ULN Cr ≤1.5 x ULN Serum total bilirubin ≤1.5 x ULN(OR ≤3 X ULN for subjects with liver metastases) AST (SGOT) and ALT (SGPT) ≤2.5 x ULN (OR ≤5 X ULN for subjects with liver metastases) 8.The subjects had no pregnancy plan and volunteered to use effective contraception and had no egg donation plan within 6 months after entering the study.
- •9.The subject will be able to communicate well with the investigator and understand and comply with the requirements of the study.
排除标准
- •1.Significant allergy, hypersensitivity or idiosyncratic reactions to doxorubicin and/or any related compounds.
- •2.Treatments were terminated due to treatment failure or serious adverse reactions in subjects who had previously used doxorubicin liposomes.
- •3.Patients with severe cardiovascular, lung, liver, kidney, gastrointestinal, endocrine, immune system, skin, musculoskeletal, neurological or psychiatric conditions that the researchers did not consider appropriate for inclusion.
- •4.Patients who had undergone major surgery within 3 months before screening, or planned to undergo major surgery during the study period.
- •5.Having a history of alcoholism, drug abuse or drug abuse. 6.The results of alcohol breath test were more than 0.0mg/100ml or drug abuse screening was positive (Methamphetamine, ketamine, MDMA,Tetrahydrocannabinol).
- •7.Pregnant or breast-feeding female. 8.Positive result to any of the following: HIV-1/2, hepatitis B and C; syphilis.
- •9.Study drug prior to radiation or the use of chemotherapy drugs less than 28 days, or other antineoplastic therapy (e.g., endocrine therapy, Chinese medicine treatment, the local radiotherapy of pain relief, etc.) is less than 14 days, or during the study period need to merge the other anti-tumor drug treatment.
- •10.Impaired cardiac function: QTc>470ms; LVEF（left ventricular ejection fraction） below 50% or below institutional normal at screening; Congestive heart failure of grade≥ 2 from NYHA classification, myocardial infarction or uncontrolled angina pectoris occurred within 6 months before enrollment; Have had bypass surgery;
- •Blood donation or massive blood loss within 90 days before screening (> 400ml) .
- •12.The total cumulative dose of doxorubicin was ≥300mg/m2 before screening, or previous administration of anthracycline caused severe cardiotoxicity.
- •13.Eating a specific diet (such as grapefruit) within 48 hours prior to enrollment can affect drug absorption, distribution, metabolism, and excretion.
- •14.Participating in other clinical trials and accepting clinical trial drugs within 28 days prior to enrollment.
- •15.Other researchers judged unsuitable for participation.
研究组 & 干预措施
Doxorubicin Hydrochloride Liposome Injection
Experimental
50mg/m2 ,IV on Day 1 of each cycle
干预措施: Doxorubicin Hydrochloride Liposome Injection (Drug)
Doxorubicin Hydrochloride Liposome Injection(Caelyx®)
Active Comparator
50mg/m2 ,IV on Day 1 of each cycle
干预措施: Doxorubicin Hydrochloride Liposome Injection (Drug)
结局指标
主要结局
Cmax
时间窗: up to 15 days post-adminstration
The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection
Tmax
时间窗: up to 15 days post-adminstration
The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection
AUC
时间窗: up to 15 days post-adminstration
The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting ConditionSolid TumorNCT05390944Impact Therapeutics, Inc.28
已完成
1 期
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed ConditionSolid TumorNCT05391048Impact Therapeutics, Inc.36
已完成
1 期
Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)HealthyNCT05135793Genuine Research Center, Egypt29
已完成
1 期
Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).HealthyNCT04657744Genuine Research Center, Egypt34
已完成
1 期
Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)HealthyNCT04478448Genuine Research Center, Egypt26